DD283564A5 - Verfahren fuer die synthese von amikacin - Google Patents
Verfahren fuer die synthese von amikacin Download PDFInfo
- Publication number
- DD283564A5 DD283564A5 DD88322213A DD32221388A DD283564A5 DD 283564 A5 DD283564 A5 DD 283564A5 DD 88322213 A DD88322213 A DD 88322213A DD 32221388 A DD32221388 A DD 32221388A DD 283564 A5 DD283564 A5 DD 283564A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- derivative
- reaction
- acylation
- amikacin
- benzyloxycarbonyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 title claims abstract description 21
- 229960004821 amikacin Drugs 0.000 title claims abstract description 19
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 230000010933 acylation Effects 0.000 claims abstract description 17
- 238000005917 acylation reaction Methods 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract 2
- 229960000318 kanamycin Drugs 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 11
- 229930182823 kanamycin A Natural products 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- 229930027917 kanamycin Natural products 0.000 claims description 5
- -1 p-nitro-benzyloxycarbonyl Chemical group 0.000 claims description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 claims description 3
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims 3
- IVUOMFWNDGNLBJ-VKHMYHEASA-N (2s)-4-amino-2-hydroxybutanoic acid Chemical class NCC[C@H](O)C(O)=O IVUOMFWNDGNLBJ-VKHMYHEASA-N 0.000 claims 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 abstract description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- SWOHHBNJQHDNFM-WYSMZKEGSA-N (2s)-4-amino-n-[(1s,2r,3r,4s,5r)-5-amino-4-[(2s,3r,4s,5s,6r)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O([C@H]1[C@H](N)C[C@@H]([C@H]([C@@H]1O)O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O SWOHHBNJQHDNFM-WYSMZKEGSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XUSXOPRDIDWMFO-CTMSJIKGSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-[(1s)-1-aminoethyl]-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(O2)[C@H](C)N)N)[C@@H](N)C[C@H]1N XUSXOPRDIDWMFO-CTMSJIKGSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- DTFAJAKTSMLKAT-JDCCYXBGSA-N 2-deoxystreptamine Chemical group N[C@H]1C[C@@H](N)[C@H](O)[C@@H](O)[C@@H]1O DTFAJAKTSMLKAT-JDCCYXBGSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- FXKSEJFHKVNEFI-GCZBSULCSA-N amikacin disulfate Chemical compound [H+].[H+].[H+].[H+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O FXKSEJFHKVNEFI-GCZBSULCSA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- RHRAMPXHWHSKQB-GGEUKFTFSA-N betamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1N RHRAMPXHWHSKQB-GGEUKFTFSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002915 carbonyl group Chemical class [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- RHRAMPXHWHSKQB-UHFFFAOYSA-N gentamicin B Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(C(O)C(O)C(CN)O2)O)C(N)CC1N RHRAMPXHWHSKQB-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- HBEQXAKJSGXAIQ-UHFFFAOYSA-N oxopalladium Chemical compound [Pd]=O HBEQXAKJSGXAIQ-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OENLEHTYJXMVBG-UHFFFAOYSA-N pyridine;hydrate Chemical compound [OH-].C1=CC=[NH+]C=C1 OENLEHTYJXMVBG-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
- C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
- C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
- C07H15/234—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Insulating Materials (AREA)
- Polymerisation Methods In General (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT8722783A IT1225484B (it) | 1987-11-27 | 1987-11-27 | Procedimento di sintesi dell'amikacina |
Publications (1)
Publication Number | Publication Date |
---|---|
DD283564A5 true DD283564A5 (de) | 1990-10-17 |
Family
ID=11200418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD88322213A DD283564A5 (de) | 1987-11-27 | 1988-11-25 | Verfahren fuer die synthese von amikacin |
Country Status (23)
Country | Link |
---|---|
US (1) | US5763587A (ja) |
EP (1) | EP0317970B1 (ja) |
JP (1) | JPH0637512B2 (ja) |
AT (1) | ATE125544T1 (ja) |
AU (1) | AU608665B2 (ja) |
BG (1) | BG49048A3 (ja) |
CA (1) | CA1324375C (ja) |
CS (1) | CS277017B6 (ja) |
DD (1) | DD283564A5 (ja) |
DE (1) | DE3854225T2 (ja) |
DK (1) | DK170050B1 (ja) |
ES (1) | ES2074431T3 (ja) |
FI (1) | FI90243C (ja) |
HU (1) | HU201771B (ja) |
IT (1) | IT1225484B (ja) |
NO (1) | NO171505C (ja) |
NZ (1) | NZ227113A (ja) |
PH (1) | PH25818A (ja) |
PL (1) | PL161416B1 (ja) |
RO (1) | RO102339B1 (ja) |
RU (1) | RU1776262C (ja) |
YU (1) | YU47063B (ja) |
ZA (1) | ZA888855B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW465235B (en) | 1998-09-17 | 2001-11-21 | United Video Properties Inc | Electronic program guide with digital storage |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
CA2622193A1 (en) * | 2005-09-29 | 2007-04-12 | Nektar Therapeutics | Antibiotic formulations, unit doses, kits, and methods |
JP5256043B2 (ja) | 2005-12-02 | 2013-08-07 | アイシス ファーマシューティカルズ, インコーポレーテッド | 複数の置換基を有する抗菌4,5−置換アミノグリコシドアナログ |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
US20080300199A1 (en) * | 2007-04-10 | 2008-12-04 | Achaogen Inc. | Antibacterial 1,4,5-substituted aminoglycoside analogs |
WO2010030690A1 (en) * | 2008-09-10 | 2010-03-18 | Isis Pharmaceuticals, Inc. | Antibacterial 4,6-substituted 6', 6" and 1 modified aminoglycoside analogs |
WO2010030704A2 (en) | 2008-09-10 | 2010-03-18 | Achaogen, Inc. | Antibacterial aminoglycoside analogs |
CN102256989B (zh) * | 2008-10-03 | 2016-01-06 | 聚糖生物科学有限责任公司 | 糖基化细菌代谢物的阴离子轭合物 |
WO2010042851A1 (en) | 2008-10-09 | 2010-04-15 | Achaogen, Inc. | Antibacterial aminoglycoside analogs |
WO2010042850A1 (en) | 2008-10-09 | 2010-04-15 | Achaogen, Inc. | Antibacterial aminoglycoside analogs |
MX2012004036A (es) | 2009-10-09 | 2012-06-27 | Achaogen Inc | Analogos de aminoglicosidos antibacterianos. |
TW201304784A (zh) | 2010-11-17 | 2013-02-01 | Achaogen Inc | 抗菌性胺基糖苷類似物 |
CN103113429B (zh) * | 2013-03-05 | 2015-02-18 | 齐鲁天和惠世制药有限公司 | 一种由阿米卡星制备硫酸阿米卡星的方法 |
CN105440090B (zh) * | 2014-08-27 | 2018-03-09 | 北大医药重庆大新药业股份有限公司 | 一种阿米卡星的合成方法 |
CN111233952A (zh) * | 2020-04-02 | 2020-06-05 | 管炫棣 | 一种阿卡米星的制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL157910B (nl) * | 1973-11-14 | 1978-09-15 | Bristol Myers Co | Werkwijze voor het bereiden van 1-(l-(-)-gamma-amino-alfa-hydroxybutyryl)kanamycine a. |
JPS51127045A (en) * | 1975-04-24 | 1976-11-05 | Microbial Chem Res Found | A process for preparing 3'- deoxykanamycin a derivatives. |
GB1530201A (en) * | 1976-04-14 | 1978-10-25 | Pfizer Ltd | Process for the preparation of aminoglycoside antibiotics and intermediates therefor |
US4136254A (en) * | 1976-06-17 | 1979-01-23 | Schering Corporation | Process of selectively blocking amino functions in aminoglycosides using transition metal salts and intermediates used thereby |
IE54288B1 (en) * | 1982-03-05 | 1989-08-16 | Fujisawa Pharmaceutical Co | New 1,4-diaminocyclitol derivatives, processes for their preparation and pharmaceutical compositions containing them |
JPS6041692A (ja) * | 1983-08-15 | 1985-03-05 | Microbial Chem Res Found | 2′,3′−ジデオキシカナマイシンa誘導体 |
IT1200774B (it) * | 1985-10-10 | 1989-01-27 | Pierrel Spa | Procedimento di sentisi dell'amikacina |
-
1987
- 1987-11-27 IT IT8722783A patent/IT1225484B/it active
-
1988
- 1988-11-23 EP EP88119460A patent/EP0317970B1/en not_active Expired - Lifetime
- 1988-11-23 DE DE3854225T patent/DE3854225T2/de not_active Expired - Fee Related
- 1988-11-23 AT AT88119460T patent/ATE125544T1/de not_active IP Right Cessation
- 1988-11-23 ES ES88119460T patent/ES2074431T3/es not_active Expired - Lifetime
- 1988-11-25 DD DD88322213A patent/DD283564A5/de not_active IP Right Cessation
- 1988-11-25 PH PH37859A patent/PH25818A/en unknown
- 1988-11-25 RU SU884356995A patent/RU1776262C/ru active
- 1988-11-25 DK DK661588A patent/DK170050B1/da not_active IP Right Cessation
- 1988-11-25 HU HU886072A patent/HU201771B/hu not_active IP Right Cessation
- 1988-11-25 NO NO885270A patent/NO171505C/no unknown
- 1988-11-25 FI FI885489A patent/FI90243C/fi not_active IP Right Cessation
- 1988-11-25 ZA ZA888855A patent/ZA888855B/xx unknown
- 1988-11-25 BG BG86218A patent/BG49048A3/xx active Active
- 1988-11-25 CS CS887779A patent/CS277017B6/cs unknown
- 1988-11-25 CA CA000584227A patent/CA1324375C/en not_active Expired - Fee Related
- 1988-11-26 JP JP63299382A patent/JPH0637512B2/ja not_active Expired - Lifetime
- 1988-11-28 AU AU25963/88A patent/AU608665B2/en not_active Ceased
- 1988-11-28 NZ NZ227113A patent/NZ227113A/en unknown
- 1988-11-28 RO RO88136098A patent/RO102339B1/ro unknown
- 1988-11-28 YU YU218888A patent/YU47063B/sh unknown
- 1988-11-28 PL PL1988276047A patent/PL161416B1/pl unknown
-
1992
- 1992-02-14 US US07/834,991 patent/US5763587A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DD283564A5 (de) | Verfahren fuer die synthese von amikacin | |
DE2332485C2 (de) | Gentamicin C1-derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE2432644A1 (de) | Derivate von desoxystreptamin enthaltenden aminoglykosid-antibiotikumderivaten und verfahren zu ihrer herstellung | |
DE2428387A1 (de) | 1,3-oxazino(5,6-c)rifamycine sowie ihre verwendung und verfahren zur herstellung derselben | |
DE2515629C3 (de) | 2"-N-substituierte Paromomycine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DD258991A1 (de) | Verfahren zur selektiven sysnthese von amikacin | |
DE2533985C2 (de) | Verfahren zur Herstellung von 3'-Desoxyneamin, kanamycin B, ribostamycin, -6'-N-methylkanamycin B und paromamin | |
DE2502296A1 (de) | Diaminocyclitol-derivate und verfahren zu ihrer herstellung | |
DE2826546C2 (ja) | ||
DE2724597B2 (de) | 3'-Desoxykanamycin C und 3',4'-Didesoxykanamycin C, deren Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende antibakterielle Mittel | |
DE2818992C2 (ja) | ||
DE2423591C3 (de) | 1-N-Isoserylkanamycine, Verfahren zu ihrer Herstellung und solche Verbindungen enthaltende Arzneimittel | |
DE2534982B2 (de) | 1-n- eckige klammer auf (l)-2-hydroxy-5-aminovaleroyl eckige klammer zu- und 1-n- eckige klammer auf (l)-2-hydroxy-6-aminocaproyl eckige klammer zu -xk-62-2, deren pharmazeutisch vertraegliche saeureadditionssalze und verfahren zu deren herstellung | |
DE2825289A1 (de) | 1-n-(omega-aminoalkansulfonyl)-derivate von aminoglycosidischen antibiotika und verfahren zur herstellung derselben | |
DE2408666C3 (de) | Antibiotische Verbindungen, deren nicht-toxische, pharmakologisch verträgliche Salze und Hydrate und Verfahren zu deren Herstellung | |
DE2817923C2 (de) | Septacidinverbindungen und diese enthaltende Arzneimittel | |
DE3308196A1 (de) | Verfahren zur herstellung von 6'-alkyl-spectinomycin sowie alkyl-spectinomycin-analogen | |
DE2720199C3 (de) | 5,6-Didesoxy-neamin und Verfahren zu dessen Herstellung | |
DE3227178C2 (de) | 2'-Modifizierte Kanamycine, Verfahren zu deren Herstellung und diese Verbindungen enthaltende antibakterielle Mittel | |
DE2436694A1 (de) | Verfahren zur herstellung von 1-n(s)-alpha-hydroxy-omega-aminoacyl)-derivaten von 3',4'-dideoxyneamin oder 3', 4'-dideoxyribostamycin | |
DE2601490C3 (de) | 3"-N-Demethylgentamycine, deren Salze mit Säuren, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung bakterieller Infektionen | |
DE2741431C3 (de) | l-N-(L-4-Amino-2-hydroxybutyryl)-3'-desoxykanamycin-C, l-N-(L-4-Amino-2hydroxybutyryl)-3',4'-didesoxykanamycin-C und deren Säureadditionssalze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende antibakterielle Zusammensetzungen | |
DE2742950C2 (de) | 4-N-Alkyl-Fortimicin B-Derivate, deren Salze und ihre Verwendung bei der Bekämpfung bakterieller Infektionen | |
DE2234315C3 (de) | L-Q-Y-Amtno-a-hydroxybutvrylderivate des Kanamycins A und B, deren nicht-toxische Säureadditionssalze und Verfahren zu deren Herstellung | |
DE1228264B (de) | Verfahren zur Herstellung von Derivaten der 7-Phenylacetamidocephalosporansaeure vom C-Typ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENJ | Ceased due to non-payment of renewal fee |